Roche, the manufacturer of medicines for cancer, has gotten approval for its skin cancer drug, Zelboraf, from European Drug Regulators.
“Today’s approval is important news for people with BRAF mutation-positive metastatic melanoma as Zelboraf significantly improves patient survival and exemplifies the benefits that Roche’s personalized approach to medicine can provide for patients, physicians and society,” said Hal Barron, M.D., Chief Medical Officer and Head, Global Product Development.
Zelboraf can be used as monotherapy for the treatment of deadly form of skin cancer. It can be taken as a pill twice a day.
Source:
SayPeople
Via:
Roche
No comments:
Post a Comment